Therefore, the objectives of this study were to compare alterations in clinicopathological features (including HER2 loss) before and after NAT and determine their impact on prognosis in patients with HER2‐positive breast cancer who did not achieve pCR. The gene discussed is ERBB2; the disease is breast cancer.